According to the NCI website BTK inhibitor LOXO-305 is an orally available, selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)

Link to National Cancer Institute

BTK inhibitor